Related Experiment Video
Updated: Jun 23, 2026
13:19
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Sequential sorafenib and sunitinib for renal cell carcinoma
M P Sablin1, S Negrier, A Ravaud
1Institut Gustave Roussy, Villejuif, France.
The Journal of Urology
|May 19, 2009
Summary
Sequential administration of sorafenib and sunitinib in renal cell carcinoma patients showed no absolute cross-resistance. Sorafenib followed by sunitinib resulted in longer overall survival compared to the reverse sequence, with good tolerability.
Area of Science:
- Oncology
- Pharmacology
Background:
- Sorafenib and sunitinib are approved tyrosine kinase inhibitors for renal cell carcinoma (RCC).
- Sequential drug administration is common due to initial treatment limitations.
Purpose of the Study:
- To evaluate the efficacy and safety of sequential administration of sorafenib and sunitinib in RCC patients.
- To determine if cross-resistance occurs between these two tyrosine kinase inhibitors.
Main Methods:
- Retrospective analysis of 90 consecutive RCC patients from France.
- Patients received either sorafenib then sunitinib, or sunitinib then sorafenib.
- Outcomes including progression-free survival and overall survival were analyzed.
Main Results:
- Median progression-free survival was 26 weeks (sorafenib) and 28 weeks (sunitinib) in the sorafenib-sunitinib group.
- Median progression-free survival was 22 weeks (sunitinib) and 17 weeks (sorafenib) in the sunitinib-sorafenib group.
- Median overall survival was significantly longer in the sorafenib-sunitinib group (135 weeks) versus sunitinib-sorafenib group (82 weeks).
- Both sequences were well-tolerated with no increased grade 3-4 toxicity.
Conclusions:
- The study suggests a lack of absolute cross-resistance between sorafenib and sunitinib in RCC.
- Sequential administration of sorafenib followed by sunitinib may be associated with improved overall survival.
- Further studies are needed to confirm these findings.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:11Renal Failure: Dose Adjustments
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...